Edwards Lifesciences Corporation’s (EW - Free Report) second-quarter 2021 adjusted earnings per share (EPS) of 64 cents surpassed the Zacks Consensus Estimate by 16.4% and improved 88.2% year over year.
GAAP EPS was 78 cents in the quarter compared with the year-ago EPS of 20 cents, reflecting a 290% surge.
Sales Details
Second-quarter net sales were $1.38 billion, up 48.8% year over year on a reported basis. On an underlying basis, growth was 44%. Moreover, the metric surpassed the Zacks Consensus Estimate by 7%.
Revenues were driven by strong sales growth across all four product groups, led by TAVR.
Segmental Details
In the second quarter, global sales in the Transcatheter Aortic Valve Replacement (TAVR) product group amounted to $901.5 million, up 51.7% from the prior-year figure on a reported basis. On an underlying basis, growth was 47.5%. Average selling prices were stable worldwide. In the United States, total TAVR sales grew 50% year over year. Outside the United States, total TAVR sales increased 40% on a year-over-year basis.
Transcatheter Mitral and Tricuspid Therapies sales totaled $22.1 million, up 259.3% from the prior-year figure on a reported basis. On an underlying basis, the improvement was 231.2%. The company continued to register strong momentum on increased adoption of the PASCAL system and activation of more centers across Europe.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Edwards Lifesciences Corporation’s (EW - Free Report) second-quarter 2021 adjusted earnings per share (EPS) of 64 cents surpassed the Zacks Consensus Estimate by 16.4% and improved 88.2% year over year.
GAAP EPS was 78 cents in the quarter compared with the year-ago EPS of 20 cents, reflecting a 290% surge.
Sales Details
Second-quarter net sales were $1.38 billion, up 48.8% year over year on a reported basis. On an underlying basis, growth was 44%. Moreover, the metric surpassed the Zacks Consensus Estimate by 7%.
Revenues were driven by strong sales growth across all four product groups, led by TAVR.
Segmental Details
In the second quarter, global sales in the Transcatheter Aortic Valve Replacement (TAVR) product group amounted to $901.5 million, up 51.7% from the prior-year figure on a reported basis. On an underlying basis, growth was 47.5%. Average selling prices were stable worldwide. In the United States, total TAVR sales grew 50% year over year. Outside the United States, total TAVR sales increased 40% on a year-over-year basis.
Transcatheter Mitral and Tricuspid Therapies sales totaled $22.1 million, up 259.3% from the prior-year figure on a reported basis. On an underlying basis, the improvement was 231.2%. The company continued to register strong momentum on increased adoption of the PASCAL system and activation of more centers across Europe.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Get the latest research report on BSX - FREE
Get the latest research report on LH - FREE
Get the latest research report on EW - FREE
Get the latest research report on WST - FREE